We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





FDA Requires Real Patient Samples for Emergency Use Authorization of COVID-19 MDx Tests

By LabMedica International staff writers
Posted on 15 May 2020
Print article
Illustration
Illustration
The US Food and Drug Administration (FDA) now requires molecular diagnostic developers to use actual positive specimens as part of its validation process for granting Emergency Use Authorization (EUA) to COVID-19 tests.

Manufacturers of assays had so far been permitted to use contrived patient samples for their EUA submissions. However, the FDA has now updated its requirements for developers seeking EUA for COVID-19 tests and use actual positive specimens as part of the validation process.

According to the FDA’s updated requirements which have been incorporated in its molecular diagnostic template for developers, a minimum of 30 positive prospective, retrospective, or leftover patient samples should be evaluated, while frozen samples are acceptable. The results must be compared to a high-sensitivity EUA RT-PCR assay, which uses a chemical lysis step, followed by solid phase extraction of nucleic acid.

"Now that there are positive patient samples, we are shifting from use of contrived samples to supplement applications to the recommendation that actual patient samples are used for the clinical performance testing," said Timothy Stenzel, director of the FDA’s office of in vitro diagnostics and radiological health. "As a result, for molecular tests the recommendation is to make comparisons to previously authorized molecular tests in order to assess whether or not accurate performance has been established."



Print article

Channels

Microbiology

view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.